US to buy “nuclear emergency” drugs as Russian MP threatens nuclear action against the United States

US to buy "nuclear emergency" drugs for $290 million as Russian MP threatens nuclear action against the United States. Image: Keith Tarrier/

THE US is set to buy “nuclear emergency” drugs for $290 million (€294 million), according to the HHS.

A day prior to a threat from a Russian MP about nuclear action against the US, the Department of Health and Human Services announced that the country was set to buy “nuclear emergency” drugs.

“HHS purchases drugs for use in radiological and nuclear emergencies,” a statement on October 4 read.

“As part of long-standing, ongoing efforts to be better prepared to save lives following radiological and nuclear emergencies, the U.S. Department of Health and Human Services is purchasing a supply of the drug Nplate from Amgen USA Inc; Nplate is approved to treat blood cell injuries that accompany acute radiation syndrome in adult and pediatric patients (ARS).”

It added: “Amgen, based in Thousands Oaks, California, developed Nplate for ARS with support from the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Administration for Strategic Preparedness and Response (ASPR), as well as the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

“BARDA is using its authority provided under the 2004 Project Bioshield Act and $290 million in Project BioShield designated funding to purchase this supply of the drug. Amgen will maintain this supply in vendor-managed inventory.

“This approach decreases life-cycle management costs for taxpayers because doses that near expiration can be rotated into the commercial market for rapid use prior to expiry and new doses can be added to the government supply.”

“ARS, also known as radiation sickness, occurs when a person’s entire body is exposed to a high dose of penetrating radiation, reaching internal organs in a matter of seconds. Symptoms of ARS injuries include impaired blood clotting as a result of low platelet counts, which can lead to uncontrolled and life-threatening bleeding,” it continued.

“To reduce radiation-induced bleeding, Nplate stimulates the body’s production of platelets. The drug can be used to treat adults and children.

“Nplate is also approved for adult and pediatric patients with immune thrombocytopenia, a blood disorder resulting in low platelet counts. Repurposing drugs for acute radiation syndrome that also are approved for a commercial indication helps to sustain availability of the product and improves healthcare provider familiarity with the drug,” it concluded.”

On Wednesday, October 5, Russian MP Yevgeny Fedorov said that the only way for Russia to win the war against Ukraine and NATO is to “launch a nuclear strike on the United States”.

“Defeating the Kyiv regime on the battlefield is impossible because we are at war with NATO,” he said.

“Unlike the Russian army, the North Atlantic Alliance has an almost endless military resource.”

He added: “It (military resource. – Ed.) is more than a hundred times larger,” as reported by

“In order for the United States to understand the seriousness of Moscow’s intentions, a new Cuban Missile Crisis must be triggered,” the MP said.

“For example, by hitting the Nevada nuclear test site with a ballistic missile,” Fedorov added.

“We will lose this war if we don’t launch a nuclear strike against the US.”

Thank you for taking the time to read this article, do remember to come back and check The Euro Weekly News website for all your up-to-date local and international news stories and remember, you can also follow us on Facebook and Instagram.

FacebookTwitterRedditWhatsAppTelegramLinkedInEmailCopy Link
Go Back
Written by

Matthew Roscoe

Originally from the UK, Matthew is based on the Costa Blanca and is a web reporter for The Euro Weekly News covering international and Spanish national news. Got a news story you want to share? Then get in touch at [email protected]


    Leave a comment

    Your email address will not be published. Required fields are marked *